H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol, Linaprazan glurate, Tegoprazan, and others, driven by improved eradication rates and safety profiles..

#CPIX #PHAT #RDHL H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

www.stocktitan.net/news/CPIX/h-pylori-infec...

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects RedHill (Nasdaq: RDHL) announced clinical and regulatory progress for RHB-102 (ondansetron) as a once-daily, bimodal extended‑release oral tablet targeting oncology support, gastroenteritis, IBS‑D and GLP‑1/GIP receptor agonist therapy–associated GI side effects.The company highlights published positive U.S. Phase 3 GUARD gastroenteritis and positive Phase 2 IBS‑D results, a positive comparative PK study for oncology support, expansion of intellectual property, and a planned Phase 2 proof‑of‑concept study for GLP‑1 GI side effects to start as early as 2026 under an accelerated FDA 505(b)(2) pathway.RedHill cites >22 million U.S. ER ondansetron prescriptions annually, >2% of Americans taking GLP‑1 drugs, and estimates up to 50% GLP‑1 discontinuation within 3 months with an associated $35 billion potential market value impact by 2030.

#RDHL #RDHL RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

www.stocktitan.net/news/RDHL/red-hill-s-rhb...

#RDHL #RDHL RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

www.stocktitan.net/news/RDHL/red-hill-bioph...

RedHill Biopharma regains Nasdaq stockholders’ equity compliance (NASDAQ:RDHL) RedHill Biopharma (RDHL) regains Nasdaq compliance as of Nov 26, 2025.

RedHill Biopharma regains Nasdaq stockholders’ equity compliance

#rdhl

Origin | Interest | Match

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement The Court has awarded more than $10.5 million in total to RedHill, comprised of the main judgment of approximately $8.6 million, now final and eligible for enforcement, and the award for legal fees and expenses of approximately $1.9 million which remains subject to appeal until March 13, 2026. 9% annual statutory interest continues to accrue on both awards.

#RDHL RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

www.stocktitan.net/news/RDHL/red-hill-annou...

RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma (Nasdaq: RDHL) received a Nasdaq Staff Determination notification on October 16, 2025 that the company did not meet the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) by the compliance date of October 13, 2025.RedHill said it intends to request a hearing before the Nasdaq Listing Qualifications Panel and that, following a transaction with Cumberland Pharmaceuticals announced October 20, 2025, it believes its stockholders' equity now exceeds the $2.5 million minimum. Submission of a hearing request will stay any delisting or suspension action and RedHill remains listed pending the Panel decision. There is no assurance the Panel will grant an extension or rule in RedHill's favor.

#RDHL RedHill Biopharma Receives Nasdaq Staff Determination Notification

www.stocktitan.net/news/RDHL/red-hill-bioph...

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO NASHVILLE, Tenn., Oct. 20, 2025/ PRNewswire/-- Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd., a specialty biopharmaceutical company, to jointly commercialize Talicia ®. The FDA-approved oral capsule is...

#CPIX #RDHL CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

www.stocktitan.net/news/CPIX/cumberland-pha...

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal RedHill (NASDAQ: RDHL) announced a strategic partnership with Cumberland Pharmaceuticals (NASDAQ: CPIX) on Oct 20, 2025 in which Cumberland will invest $4.0 million for a 30% ownership stake and joint control of RedHill's Talicia business, with RedHill retaining 70%.The companies agreed an equal-sharing U.S. co-commercialization deal for Talicia's net revenues, with Cumberland providing national sales, marketing and operational support. Talicia is patent protected through 2042 and holds eight years of U.S. QIDP exclusivity. The transaction also contributes to RedHill's belief that it has stockholders' equity above the $2.5 million Nasdaq continued-listing threshold as of the press release date.

#RDHL #RDHL #CPIX RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

www.stocktitan.net/news/RDHL/red-hill-s-tal...

(Nasdaq: #RDHL)
#RedHillBiopharma expands Talicia’s reach with a new $1.8M+ licensing deal in the Middle East, bringing its FDA-approved, antibiotic-resistance-targeted H. pylori therapy to regions with some of the world’s highest infection rates.
prismmarketview.com/redhill-biop...

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® RedHill Biopharma (NASDAQ: RDHL) signed a licensing agreement to commercialize Talicia in new Middle East markets on Oct 6, 2025. The deal provides $500,000 guaranteed (including a $250,000 upfront payment and $250,000 fixed within 18 months), plus a minimum of $1.3 million in potential near-term milestone payments and tiered royalties up to mid‑teens% on Talicia net sales.Talicia is described as the only FDA‑approved all‑in‑one, low‑dose rifabutin‑based H. pylori therapy, listed as a first‑line option in ACG guidelines, patent‑protected through 2042, and granted eight years of U.S. exclusivity under QIDP.

#RDHL #RDHL RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

www.stocktitan.net/news/RDHL/red-hill-bioph...

Trade Alerts, Monday September 29, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading Mon Sept 29th - #YCBD #ZURA #VALN #TLRY #SCOR #RDHL #NTWK #INVZ #GRWG #CRON #ACB #WOLF #CGC - More: crystalequityresearch.com/trade-alerts... - #smallcap

$10 Million Legal Victory: RedHill Biopharma Wins NY Supreme Court Battle, Gains Asset Freeze NY Supreme Court upholds $8.25M judgment plus $1.82M in legal costs against Kukbo, rules RedHill fulfilled obligations. Korean court grants asset freeze for enforcement.

#RDHL #RDHL RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

www.stocktitan.net/news/RDHL/red-hill-wins-...

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights RedHill Biopharma (NASDAQ:RDHL) reported its H1 2025 financial results, showing significant operational improvements. Net revenues increased 59% to $4.1 million compared to H1 2024, with Talicia net revenues reaching $3.8 million. The company achieved a doubled gross profit and reduced operating loss to $4.4 million from $8.4 million year-over-year.Key developments include the initiation of a Bayer-supported Phase 2 study for opaganib in prostate cancer, positive FDA feedback for RHB-204 in Crohn's disease, and an up to $60 million global licensing deal with Hyloris Pharmaceuticals for RHB-102. The company secured additional Talicia formulary coverage for 8 million more lives, reaching over 204 million covered lives total.Financial stability was enhanced with $13.5 million available through ATM and Market Purchase agreements, while maintaining a cash balance of $3 million as of June 30, 2025.

#RDHL RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/RDHL/red-hill-bioph...

$10M Total Court Victory: RedHill Biopharma Secures Additional $1.8M Legal Cost Award in NY Supreme Court NY Supreme Court awards RedHill Biopharma $1.82M in legal costs, supplementing prior $8.25M judgment vs Kukbo. Both awards include 9% interest. Korean court grants asset attachment.

#RDHL RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

www.stocktitan.net/news/RDHL/red-hill-bioph...

90% H. Pylori Eradication: RedHill's Talicia Hits First Global Sales Milestone with Patent Until 2042 RedHill's Talicia, the #1 gastroenterologist-prescribed H. pylori treatment, achieves $1.1M in milestone payments and royalties. Shows 90% efficacy vs. 68.5% for traditional therapy.

#RDHL RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

www.stocktitan.net/news/RDHL/red-hill-recei...

RedHill Biopharma Shares up 75% After Securing FDA Backing for Novel Crohn’s Disease Therapy RHB-204 RedHill Biopharma (RDHL) has received positive guidance from the U.S. Food and Drug Administration on its planned clinical pathway for RHB-204, a next-generatio

#RDHL
#RedHillBio surges ~75% after scoring positive FDA feedback on its novel Crohn’s therapy RHB‑204—a targeted oral drug for MAP‑positive patients.
prismmarketview.com/redhill-biop...

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease RedHill Biopharma (NASDAQ:RDHL) has received positive FDA feedback for its groundbreaking RHB-204 Crohn's disease treatment program. The FDA guidance enables a novel Phase 2 study targeting Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease patients - the first of its kind.RHB-204, patent-protected until 2041, is an optimized formulation of RHB-104, which demonstrated 64% improved efficacy in Phase 3 trials. The drug features a 40% reduced pill burden and enhanced tolerability. The company has established collaborations with academic centers for advanced MAP detection diagnostics, addressing a previous major development barrier.The Crohn's disease market is projected to grow from $13.6 billion in 2024 to over $19 billion by 2033. The company expects non-dilutive funding for the program and anticipates benefits including pediatric orphan drug designation transfer and potential breakthrough therapy status.

#RDHL RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

www.stocktitan.net/news/RDHL/red-hill-recei...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer RedHill Biopharma (NASDAQ: RDHL) has initiated patient recruitment for a Phase 2 study evaluating opaganib in combination with darolutamide for treating metastatic castrate-resistant prostate cancer (mCRPC). The study, sponsored by ANZUP and supported by Bayer and Ramsay Hospital Research Foundation, will be conducted across 10 sites in Australia and New Zealand.The 60-participant placebo-controlled randomized study will utilize the PCPro™ lipid biomarker test to identify poor-prognosis patients who may benefit from the combination therapy. The study's primary endpoint is improved 12-month radiographic progression-free survival (rPFS). Professor Lisa Horvath from Sydney's Chris O'Brien Lifehouse will lead the research.The study aims to address prostate cancer, which is the second most diagnosed cancer globally with approximately 1.5 million new cases and 400,000 deaths annually. The global prostate cancer market is valued at approximately $12 billion.

#RDHL RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

www.stocktitan.net/news/RDHL/red-hill-bioph...

on big news! 📈 RedHill Biopharma wins $8.25M court ruling + asset freeze on Kukbo in South Korea. Pulled back to $2.10, now $2.04 pre-market (+2%). Vol at 1.03M vs. 237K avg—can the bull run continue with this low float (1.77M)? 👀 #RDHL #Biopharma #Catalyst #StockSpike

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win RedHill Biopharma (NASDAQ: RDHL) has secured a significant legal victory in its ongoing dispute with Kukbo Co. Ltd. The Incheon District Court in Korea has granted an asset freeze on Kukbo's assets, following RedHill's successful $8.25 million plus legal fees summary judgment win in the New York Supreme Court.The judgment stems from Kukbo's failure to honor subscription and licensing agreements signed in October 2021 and March 2022. The total amount includes $1.75 million in accrued interest at 9%. While Kukbo filed a notice of appeal on December 4, 2024, they have until June 4, 2025, to perfect their appeal, subject to potential extension. The New York Supreme Court has dismissed all of Kukbo's counterclaims.

#RDHL RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

www.stocktitan.net/news/RDHL/red-hill-bioph...

H. Pylori Treatment Revolution: Top Experts Join Forces in Groundbreaking Medscape Education Program New CME program tackles H. Pylori resistance with leading gastroenterology experts. Learn latest treatment protocols for this WHO Group 1 carcinogen. Get insights now.

#RDHL RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

www.stocktitan.net/news/RDHL/red-hill-suppo...

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 RedHill Biopharma (RDHL) has secured a key Chinese patent for RHB-107, its COVID-19 treatment candidate. The patent, granted by China National Intellectual Property Administration, covers the compound's molecular structure and its use in treating SARS-CoV-2 infections, including variants.The company's Phase 2 study demonstrated promising results with 100% reduction in COVID-19 hospitalization (0/41 patients on RHB-107 vs 3/20 on placebo) and approximately 88% reduction in new severe COVID-19 symptoms (2.4% RHB-107 vs 20% placebo). Recovery time was notably faster at 3 days with RHB-107 compared to 8 days with placebo.RHB-107 is an oral, once-daily, host-directed antiviral designed to act independently of viral spike protein mutations. The patent strengthens RedHill's position in the global COVID-19 therapeutic market, projected to be worth over $3 billion in 2025.

#RDHL RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

www.stocktitan.net/news/RDHL/red-hill-bioph...

RedHill Biopharma Must Address $4.7M Equity Shortfall to Maintain Nasdaq Listing Status Biotech firm reports $4.7M stockholders' deficit, triggering Nasdaq minimum equity requirement notice. 45-day deadline to submit compliance plan. See timeline.

#RDHL RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

www.stocktitan.net/news/RDHL/red-hill-bioph...

Game-Changing Oral Alternative to Ozempic: RedHill's Drug Matches Weight Loss Efficacy First-in-class oral obesity drug demonstrates Ozempic-like efficacy with potential advantages. Novel mechanism targets $100B market. See full clinical implications.

#RDHL RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

www.stocktitan.net/news/RDHL/red-hill-bioph...

Breaking News: ( NASDAQ: #RDHL ) RDHL - Historical Earnings Price Analysis

BREAKING NEWS: ( NASDAQ: #RDHL ) RDHL - Historical Price Movements Surrounding Earnings